



**Conference
Programme**

15th & 16th May 2017 • Belfast Waterfront

SEBBIN PARIS
ESTHETIQUE & RECONSTRUCTION

Visit booth #5
to learn more about
our solutions for
breast reconstruction

Sebbin is a Paris-based medical
device company with over
30 years experience in aesthetic
and reconstructive surgery.



Recreating harmonious bodies
for a new vision of rebirth.

www.sebbin.com

Anatomical Breast Implants

Meso BioMatrix®

Acellular Peritoneum Matrix

Lipo'art solutions
for fat transfer and liposuction

New expander
with integrated valve
coming soon!



TruNode®
FROM **faxitron**

Single-use Wireless Gamma Probe

More Sensitive. Less Invasive.

TruNode is optimized for the most common
radio-guided surgical procedures.

To find out more..

Visit us at Stand 31



daax.co.uk
0870 979 9110

daax

President's Welcome



Welcome to the 2017 ABS Conference in Belfast. The conference centre is located in a stunning redeveloped venue overlooking the Lagan river. I hope you have a chance to enjoy the central city location, close to the famous Harland and Woolf shipyards, but with the glorious Northern Ireland countryside as a backdrop. Since the cessation of the 'Troubles' in 1998 Belfast has transformed itself into a city of culture and industry, embodying the famed Irish hospitality.

No visit to Belfast would be complete without visiting Titanic Belfast, the location of the conference dinner. Dress up and let out your inner Leonardo di Caprio or Kate Winslet on the glamorous sweeping Titanic staircase. Enjoy the evening's entertainment and music, put on your dancing shoes and party the

night away but make sure you are up bright and early for day two of the conference and your chance to breakfast with the Trustees (see details elsewhere in the programme).

The conference has something for everyone, reflecting the breadth and depth of modern specialist breast surgery and care both in the UK and abroad. We welcome our local, European and international experts: Amy Degnim from The Mayo is our BJS plenary speaker discussing 'Are benign changes truly benign?' The title echoes a long overdue re-focus on benign breast issues many of which are not so benign and are very troublesome to our patients.

With regards to oncoplastics we are well served by Jaume Masia from Hospital de la Santa Creu I Sant Pau, Barcelona and Alberto Rancati from the Oncology Institute of Buenos Aires with Roger Wixtrom and Mark Clemens from the USA discussing the thorny and topical issue of biofilms and BIA-anaplastic large cell associated lymphoma. In addition Pat Whitworth has kindly agreed to update his earlier work on minimally invasive lumpectomy for small breast cancers and ADH. Lastly but definitely not least, our very own world renowned oncoplastic expert, Dick Rainsbury, is sharing his wealth of experience.

We are very grateful to Carmel Malone, President of the Society of Irish Breast Surgeons, for organising what will be an excellent and interactive session on one of our most difficult clinical scenarios – loco

regional management after primary chemotherapy. ABS has partnered with Symposium Mammographicum who have put together an excellent session on modern breast imaging reflecting the importance of MDT working and in particular the close working relationship between surgeons, specialist nurses and radiology services. As always the nursing session will be packed out by all members of the MDT.

The hot topics session should be lively and interesting: Olly Branford, the international medicine and social media guru, has kindly agreed to share his vision of the importance of engaging with and using social media as a force for good as well as a valuable resource and educational tool.

We had a record number of high quality abstracts carefully reviewed and ranked by the abstract committee so there is going to be strong competition for the poster prize.

Finally we are paying tribute to Professor Adele Francis after her untimely death earlier this year. Her vision of breast surgery research will drive the new ABS research objective 'every patient in a surgery trial'.

It is an amazing programme: the difficulty will be choosing where to be at any one time. Please enjoy your time in Belfast.

A handwritten signature in blue ink that reads "Fiona MacNeill". The signature is written in a cursive, flowing style.

Fiona MacNeill
ABS President

QUALITY AND CHOICE



LASTING SHAPE PROVEN SCIENCE

Over 35 years manufacturing experience in anatomical implants, offering individual solutions leading to long-term patient satisfaction:

- 97% patient satisfaction at up to 9 years after surgery.¹
- Up to 11 years after surgery, most patients reported improved self-esteem, body perception, feeling of wearing clothes, personal charisma and attraction ability.²

The anatomical design provides a natural, proportionate breast shape^{3,4} - Form Stable gel ensures that shape remains predictable and long lasting with lower complication rates.^{2,4}

The Natrelle® 410 is one of the few FDA licensed anatomical implants marketed in Europe, Africa and the Middle East:



REFERENCES

1. Hedén P, et al (2006). Style 410 Cohesive Silicone Breast Implants: Safety and Effectiveness at 5 to 9 Years after Implantation. *Plast. Reconstr. Surg.* 118(6), 1281-1287. 2. Hedén P, et al (2009). Long-Term Safety and Effectiveness of Style 410 Highly Cohesive Silicone Breast Implants. *Aesth Plast Surg.* 33, 430-436. 3. Abramo A C, et al (2009). How Texture-Inducing Contraction Vectors Affect the Fibrous Capsule Shrinkage Around Breast Implants. *Aesth Plast Surg* 34:555-560. 4. Adams W (2007). Form-Stable Cohesive Gel Implants: Advantages and Technical Essentials. *Innovations in Plastic Surgery*. 1(3), 7-14
* Different ranges are approved and available in different regions/countries



Date of preparation: October 2014 UK/1041/2014

MENTOR® CPG™ GEL BREAST IMPLANTS



10 YEARS THAT SHAPED BREAST AESTHETICS. CORE STUDY¹

TEXTURE YOU CAN TRUST

PROVEN RESULTS THAT YOU CAN TRUST

By manufacturing an implant with our unique SILTEX™ Imprinted Texture, we have created a surface substantially free of pores and interstices² which can contribute to a reduction in key complications during breast augmentation.^{3,4}

For further information about MENTOR® CPG™ Gel Breast Implants, talk to your Mentor Sales Representative or visit mentorwwllc.eu for more information.

LOWEST	LOW	NO
Reported incidence of the following complications at 10 years ^{1*}	Complication risk in over 9000 SILTEX™ Texture Implants ⁵	Silicone particulates left behind ⁶
3.8% Capsular contracture in primary augmentation ¹	0% 0% reported double capsule based upon reported clinical studies ¹	0 out of 5 No (0) particles suspected to be silicone globules were found in the capsular tissue of 5 patients implanted with SILTEX™ Texture devices ⁶
1.5% Rotation in primary augmentation ¹		

*Not a head to head comparison. Based on 10 year core clinical study reported data of CPG™ Gel Breast Implants, NATRELLE™ 410 TruForm™ 3 Gel Breast Implants, NATRELLE™ Round TruForm™ 1 Gel Breast Implants, and MemoryGel™ Breast Implants. These core clinical studies DID NOT include NATRELLE™ Inspira Round TruForm™ 1 Gel Breast Implants, NATRELLE™ 410 TruForm™ 2 Gel Breast Implants, or NATRELLE™ 510 Dual Gel Anatomical Breast Implants. Only clinical studies with 10 year data were considered.

1. Mentor Worldwide LLC. MemoryShape® Post-Approval Cohort Study (formerly Contour Profile Gel Core Study) Annual Report. June 2014. 2. United States Patent Number 4,960,425. Yan et al. 3. Textured Silicone Breast Implant Use in Primary Augmentation. Core Data Update and Review. Brian M. Derby, MD, Mark A. Codner, MD. 4. Wixtrom R, Vargo J, Canady J. Controversies in Breast Implant Texturing: New evidence on friction, rotation, double capsules and interactive effect of device placement on contracture in primary augmentation. Paper presented at IQAM Congress and Consensus Conference. 10 April 2014. Budapest. 5. Mentor's Core and Continued Access studies for round and shaped breast implants. 6. Danino AM et al. *Plast Reconstr Surg*. 2001;108:2047-2052.

ABS Conference

15th & 16th May 2017 • Belfast Waterfront

Monday 15th May 2017 – At a glance

	Auditorium	Studio	Hall 2B
09:00 to 10:30	Session 1 Reducing margin re-excisions: A MDT effort	Session 2 Submitted papers	
10:30 to 11:00 Tea and Coffee Break (Hall 1)			
11:00 to 12:30	Session 3 Breast cancer related lymphoedema	Session 4 Clinical Practice & Standards session	Session 5 Submitted papers
12:30 to 12:40	Introduction of the new ABS President		
12:40 to 14:10 Lunch Break (Hall 1)			
12:40 to 13:25	ABS AGM (open to ABS members only)		
14:10 to 14:40	Session 6 EJSO Lecture		
14:45 to 16:15	Session 7 Benign breast problems - An update	Session 8 Hot topics I	Session 9 BJS Prize papers
16:15 to 16:45 Tea and Coffee Break (Hall 1)			
16:45 to 18:15	Session 10 Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)	Session 11 Academic and Research session	Session 12 Oncology Update
18:15 to 19:00 Drinks reception (Hall 1)			
18:20 to 18:50 Poster Prize Session (Hall 2A)			

Monday 15th May 2017

SESSION 1

09:00 to 10:30: Auditorium	
Reducing margin re-excisions: a MDT effort	
<i>Chairs: Mrs Katy Hogben & Mr Michael Sugrue</i>	
09:00 to 09:15	Are margins still important? <i>Dr Gerry Hanna, Queen's University, Belfast</i>
09:15 to 09:30	Should radiologists look harder? <i>Dr Barbara Dall, St James's University Hospital, Leeds</i>
09:30 to 09:45	Are pathologists looking too hard? <i>Dr Clinton Boyd, Antrim Area Hospital</i>
09:45 to 10:00	Margin assessment: Disruptive innovation or traditional disruptions <i>Mr Daniel Leff, Imperial Healthcare & Imperial College London</i>
10:00 to 10:20	MDT case discussions <i>Mr Edward St John, Imperial College Healthcare NHS Trust</i>
10:20 to 10:30	Discussion

Monday 15th May 2017

SESSION 2

09:00 to 10:30: Studio

Submitted papers

Chairs: Mr Robert Kennedy & Miss Anne Tansley

09:00 to 09:10	1. Outcome following 150 prepectoral implant based breast reconstruction using Braxon® (ADM): UK experience <i>Miss Raghavan Vidya, Royal Wolverhampton Hospital</i>
09:10 to 09:20	2. Magseed - Safety and feasibility study of the use of magnetic marker seeds to localise breast cancers <i>Mr James Harvey, University Hospital of South Manchester</i>
09:20 to 09:30	3. Three 3D measurements could replace panel assessment for evaluation of aesthetic outcome after Breast-Conserving Therapy (BCT) <i>Miss Amy Godden, The Royal Marsden NHS Foundation Trust, Sutton</i>
09:30 to 09:40	4. Breast Arterial Calcification on screening mammography can predict clinically significant coronary artery disease (CAD) in the BreastCheck screening cohort <i>Ms Emer Scanlan, St Vincent's University Hospital, Dublin</i>
09:40 to 09:50	5. The potential role of three dimensional surface imaging (3D-SI) derived symmetry score of breasts as an objective measure of aesthetic outcome after breast conserving therapy (BCT) <i>Miss Rachel O'Connell, Royal Marsden NHS Foundation Trust, Sutton</i>
09:50 to 10:00	6. Rates of secondary surgery following immediate post-mastectomy reconstruction in English NHS hospitals: A national cohort study of 13,736 women <i>Mr Joe O'Donoghue, Royal Victoria Infirmary, Newcastle upon Tyne</i>
10:00 to 10:10	7. Dedicated under 35 breast clinic: is this the answer? <i>Ms Ruvinder Athwal, New Cross Hospital, Wolverhampton</i>
10:10 to 10:20	8. Poor overall survival in male breast cancer patients negative for CK18 and CK19 <i>Mr Sreekumar Sundara Rajan, Leeds Institute of Cancer and Pathology</i>

SESSION 3

11:00 to 12:30: Auditorium

Breast cancer related lymphoedema

Chairs: Mr Simon Cawthorn & Mrs Maria Noblet

11:00 to 11:25	Pathophysiology, measurement and non-surgical management of breast cancer related lymphoedema <i>Prof Jaume Masia, Hospital de la Santa Creu I Sant Pau, Barcelona</i>
11:25 to 11:45	Myths of lymphoedema, reverse mapping and LYMPHA <i>Mr Paul Thiruchelvam, Imperial College Healthcare NHS Trust</i>
11:45 to 12:00	LVA & vLNT for lymphoedema <i>Mr Kelvin Ramsey, The Royal Marsden NHS Foundation Trust</i>
12:00 to 12:15	Liposuction for lymphoedema <i>Mr Alex Munnoch, Ninewells Hospital, Dundee</i>
12:15 to 12:30	Discussion



Webcasts of most of the presentations from the conference will be available shortly on the ABS website

www.associationofbreastsurgery.org.uk

Monday 15th May 2017

SESSION 4

11:00 to 12:30: Studio

Clinical Practice and Standards session

Chairs: Mr Giles Cunnick & Mr Ashu Gandhi

11:00 to 11:10	National Audit of Breast Cancer in Older Patients (NABCOP) <i>Prof Kieran Horgan, Leeds Teaching Hospitals NHS Trust</i>
11:10 to 11:25	B3 Guidelines <i>Prof Sarah Pinder, Guy's Hospital, London</i>
11:25 to 11:50	NHS BSP & ABS Audit of screen-detected breast cancers 2015-16 & surgical KPIs <i>Mr Giles Cunnick, Wycombe Hospital & Mr Ashu Gandhi, South Manchester University Hospital</i>
11:50 to 12:05	Nationwide study of outcomes after DCIS 1971 – 2014 <i>Mr Gurdeep Mannu, University of Oxford</i>
12:05 to 12:15	LORIS <i>Mrs Jacquie Jenkins, Programme Manager, NHS Breast Screening Programme & Miss Cliona Kirwan, University Hospital of South Manchester</i>
12:15 to 12:30	Discussion

SESSION 5

11:00 to 12:30: Hall 2B

Submitted papers

Chairs: Ms Karina Cox & Mr James Harvey

11:00 to 11:10	9. Close margins, radiotherapy and outcomes in screen-detected ductal carcinoma in situ (DCIS) <i>Mrs Karen Clements, The Sloane Project</i>
11:10 to 11:20	10. Variables associated with margin re-excision in breast conserving therapy (BCT) - Results from the National Margins Audit <i>Ms Sarah Tang, St George's Hospital, London</i>
11:20 to 11:30	11. The impact of surgical site infections on breast cancer recurrence rates - single centre experience <i>Dr Conor Toale, St James's Hospital, Dublin</i>
11:30 to 11:40	12. National Margins Audit - Results of current practice questionnaire <i>Ms Sarah Tang, St George's Hospital, London</i>
11:40 to 11:50	13. Tubular and mucinous breast cancer: can sentinel node biopsy be safely omitted? <i>Ms Elizabeth Morrow, Glasgow University</i>
11:50 to 12:00	14. Digital procedure specific consent forms (OpInForm) compared to handwritten surgical consent forms in breast surgery <i>Mr Edward St John, Imperial College, London</i>
12:00 to 12:10	15. Core biopsy is more sensitive than fine needle aspiration for preoperative axillary staging in invasive breast cancer. <i>Ms Elizabeth Morrow, Glasgow University</i>
12:10 to 12:20	16. Audit of the routine introduction of Oncotype DX testing in a single breast unit <i>Ms Nikki Green, Gloucestershire Hospitals NHS Foundation Trust</i>

12:30 to 13:25 Auditorium

Introduction of the new ABS President and ABS AGM

All delegates are invited to an introduction to the new ABS President, Mr Mark Sibbering, in the auditorium at 12.30. The ABS AGM will be held in the same room at 12.40. All ABS members are encouraged to attend this meeting.

SESSION 6

14:10 to 14:40: Auditorium

EJSO Lecture

Chair: Mr Mark Sibbering

Use of robotics in training

Dr Alberto Rancati, Instituto Oncologico Henry Moore, Buenos Aires

Monday 15th May 2017

Session 7

14:45 to 16:15: Auditorium

Benign breast problems - An update

Chairs: Miss Nicky Roche & Ms Sam Sloan

14:45 to 15:00	Granulomatous conditions <i>Dr Elizabeth Mallon, NHS Greater Glasgow & Clyde</i>
15:00 to 15:15	Fibroadenomas/ phyllodes <i>Ms Karina Cox, Maidstone & Tunbridge Wells NHS Trust</i>
15:15 to 15:30	Papillomatosis <i>Ms Jennifer Hu, St Bartholomew's Hospital, London</i>
15:30 to 15:45	Pseudo-angiomatous stromal hyperplasia (PASH) <i>Dr Rahul Deb, Royal Derby Hospital</i>
15:45 to 16:00	Fibromatosis <i>Mr Robert Ashford, University Hospitals of Leicester</i>
16:00 to 16:15	Discussion

Session 8

14:45 to 16:15: Studio

Hot topics I

Chairs: Mr Giles Cunnick & Miss Julie Doughty

14:45 to 15:10	Minimally-invasive, sutureless, stereo-guided lumpectomy for small breast cancers and ADH: Making the treatment match the disease <i>Dr Pat Whitworth, Nashville Breast Center, USA</i>
15:10 to 15:30	Social media and medicine <i>Mr Olivier Branford, Royal Marsden Hospital</i>
15:30 to 15:55	Breast conserving surgery versus mastectomy: Is it now time to stop giving patients a choice? <i>Mr Michael Dixon, Western General Hospital, Edinburgh</i>
15:55 to 16:15	Should all hormone receptor positive breast cancer patients be offered extended endocrine therapy? <i>Prof John Benson, Addenbrooke's Hospital, Cambridge</i>

Session 9

14:45 to 16:15: Hall 2B

BJS Prize papers

Chairs: Mr Daniel Leff & Prof Malcolm Reed

14:45 to 14:55	17. A time for change; the need to modernise breast surgery training. Results of surveys of senior breast trainees and of current consultant practice <i>Mr Rajiv Dave, Mammory Fold, National Trainee Representatives</i>
14:55 to 15:05	18. Rapid Evaporative Ionisation Mass Spectrometry of surgical vapours towards an Intelligent Knife for precision breast surgery <i>Mr Edward St John, Imperial College, London</i>
15:05 to 15:15	19. Prevalence and tumour characteristics of contralateral breast cancer over 5 years in a tertiary-referral cancer centre <i>Dr XT Tan, St Vincent's University Hospital, Dublin</i>
15:15 to 15:25	20. Radioactive iodine-125 seed localisation of breast carcinoma in advance of the day of surgery reduces pre-operative anxiety levels <i>Mr Robert Pearson, Newcastle Hospital Trust</i>
15:25 to 15:35	21. Development and validation of a predictive risk model for acute skin toxicity in patients undergoing breast radiotherapy <i>Mr Tim Rattay, University of Leicester</i>
15:35 to 15:45	22. Can axillary node clearance (ANC) be avoided in selected clinically node positive breast cancers (cN+BC) after neoadjuvant therapy (NAT)? <i>Ms Ilaria Giono, University College London Hospital</i>
15:45 to 15:55	23. A systematic review and meta-analysis of aberrant lymphatic drainage in recurrent breast cancer <i>Mr Muneer Ahmed, King's College London</i>
15:55 to 16:05	24. Outcomes of primary endocrine therapy for operable breast cancer in the elderly: Initial results from the regional North East study <i>Mr Robert Thomas, Gateshead NHS Trust</i>

Monday 15th May 2017

Session 10

16:45 to 18:15: Auditorium

Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)

Chairs: Miss Fiona MacNeill & Mr Philip Turton

16:45 to 17:10	ALCL: A world overview and reclassification <i>Dr Mark Clemens, MD Anderson Cancer Center, Texas, USA</i>
17:10 to 17:25	UK ALCL data <i>Miss Laura Johnson, Barts Health NHS Trust, London</i>
17:25 to 17:50	BIA-ALCL, biofilms and prophylaxis considerations <i>Dr Roger Wixtrom, LSCI, Springfield, USA</i>
17:50 to 18:05	The pathogenesis of ALCL; molecular mechanism & cell of origin <i>Dr Suzanne Turner, University of Cambridge</i>
18:05 to 18:15	Discussion

Session 11

16:45 to 18:15: Studio

Academic and Research session

Chairs: Mr Ramsey Cutress & Prof Malcolm Reed

16:45 to 17:05	Transforming surgical research <i>Prof Dion Morton, University of Birmingham</i>
17:05 to 17:15	Discussion
17:15 to 17:35	Mind the gap – opportunities and priorities for breast cancer surgery research <i>Mr Ramsey Cutress, University Hospital Southampton NHS Foundation Trust & Miss Shelley Potter, Royal Liverpool University Hospital & University of Bristol</i>
17:35 to 17:45	Discussion
17:45 to 18:15	ABS research development grants updates:
	An exploratory study of breast cancer initiating events in BRCA1 mutation carriers <i>Mr Stuart McIntosh, Queen's University Belfast (joint grant with Prevent Breast Cancer)</i>
	The TeaM (Therapeutic Mammoplasty) Study – A national audit of the practice and outcomes of therapeutic mammoplasty <i>Miss Elizabeth Baker, on behalf of the Mammary Fold Academic and Research Collaborative & the TeaM Study Steering Group</i>
	Intra-operative rapid evaporative ionisation mass spectroscopy for oncological margin control in breast conserving surgery – towards an Intelligent Knife for breast cancer surgery <i>Mr Daniel Leff, Imperial College London</i>
	Can text message reminders improve uptake of breast screening? A RCT <i>Miss Sarah Huf, Imperial College London (joint grant with Prevent Breast Cancer)</i>
	Identifying research through public and patient perspectives and priorities (4Ps study) <i>Mr George Boundouki for the North West Breast Trainees Collaborative</i>
	Magnetic occult lesion localization (MOLL) for non-palpable breast cancer <i>Mr Muneer Ahmed, Guy's Hospital, London</i>

Conference Evaluation

Delegates are requested to complete their conference evaluation online via the App or the ABS website

www.associationofbreastsurgery.org.uk

A free delegate registration for the ABS Conference 2018 is on offer to the first person, picked at random, from those completing the online evaluation by the 23rd May 2017.

Monday 15th May 2017

Session 12

16:45 to 18:15: Hall 2B

Oncology update

Chairs: Miss Leena Chagla & Ms Lis Grimsey

16:45 to 17:05	Bone Health and adjuvant bisphosphonates <i>Dr Catherine Harper-Wynne, Maidstone and Tunbridge Wells NHS Trust</i>
17:05 to 17:25	Update on current and future oncology treatments <i>Dr Mark Harries, Guys & St Thomas' NHS Trust</i>
17:25 to 17:45	The interface between acute oncology and breast care nursing <i>Ms Phillipa Jones, NIHR West Midlands</i>
17:45 to 18:05	Examining cognitive functions in breast cancer patients prior to surgery <i>Dr Helena Harder, SHORE-C, Brighton and Sussex Medical School</i>
18:05 to 18:15	Discussion

18:20 to 18:50: Hall 2A

Poster Prize Session

Chair: Mrs Katy Hogben

Oral presentation of the best 6 posters



oncotype DX[®]
Breast Recurrence Score

- is the only genomic assay validated to predict chemotherapy benefit^{1,2}
- reveals tumour biology beyond traditional parameters¹⁻⁵
- has the highest level of evidence (1A) and a proven 10-year track record^{6,7,8,9}

INFORMING
LIFE DECISIONS

NICE Breast Cancer Quality Standard [QS12] recommends Oncotype DX[®] testing.

(June 2016, www.nice.org.uk/Guidance/QS12)

Visit us at www.oncotypedx.com

References 1. Albain et al. *Lancet Oncol.* 2010. 2. Paik et al. *J Clin Oncol.* 2006. 3. Dowsett et al. *J Clin Oncol.* 2010. 4. Goldstein et al. *J Clin Oncol.* 2008. 5. Paik et al. *N Engl J Med.* 2004. 6. Gluz et al. *J Clin Oncol.* 2016. 7. Sparano et al. *N Engl J Med.* 2015. 8. Genomic Health. 2016. Data on file. 9. Simon et al. *J Natl Cancer Inst.* 2009.

This piece is intended to educate physicians on the clinical utility of the Oncotype DX Breast Recurrence Score[®] assay and should not be provided to patients. Genomic Health, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype IQ, Genomic Intelligence Platform and Making cancer care smarter are trademarks or registered trademarks of Genomic Health, Inc. © 2017 Genomic Health, Inc. All rights reserved. GHI11085_0317_EN_UK

Making cancer care smarter.™

oncotype IQ[®]
Genomic Intelligence Platform

Genomic Health[®]
LIFE. CHANGING.

Meet the Trustees

Tuesday 16th May 2017, 08:15 to 09:00 • Hall 2A

The ABS Trustees will be available to answer any questions from members or discuss any issues during a breakfast session on Tuesday morning. The Trustees want to understand what professional concerns are engaging ABS members and see if there are any common themes that need to be addressed at a wider level through the organisation's activities and CPD.

Tuesday 16th May 2017 – at a glance

	Auditorium	Studio	Hall 2B
09:00 to 10:30	Session 13 SIBS' session: Breast surgery in the neoadjuvant era	Session 14 Symposium Mammographicum session: New imaging techniques - what you need to know	Session 15 Mammary Fold session
10:30 to 11:00 Tea and Coffee Break (Hall 1)			
11:00 to 12:30	Session 16 Oncoplastic & Aesthetic Surgery	Session 17 Personalised medicine: Biomarkers, biobanking and genomics for breast surgeons	Session 18 Nursing hot topics
12:35 to 12:55	Session 19 The role of ABS in promoting research		
12:55 to 13:55 Lunch (Hall 1)			
13:55 to 14:25	Session 20 BJS Lecture		
14:30 to 16:00	Session 21 Hot Topics II	Session 22 Submitted papers	

Session 13

09:00 to 10:30: Auditorium	
Society of Irish Breast Surgeons' session: Breast surgery in the neoadjuvant era	
<i>Chairs: Mr Dhafir Alazawi & Ms Carmel Malone</i>	
09:00 to 09:15	Neo-adjuvant chemotherapy and breast surgery: A help or hindrance? <i>Ms Ruth Prichard, St Vincent's University Hospital, Dublin</i>
09:15 to 09:30	Sentinel Node Biopsy – before, after or never with neoadjuvant treatment? <i>Prof Elizabeth Connolly, St James's University Hospital, Dublin</i>
09:30 to 10:00	Case presentations Moderator: <i>Prof Michael Kerin, National University of Ireland, Galway</i> Case Presenters: <i>Mr Colm Power, Beaumont Hospital, Dublin</i> <i>Mr Dhafir Alazawi, St James's Hospital, Dublin</i> <i>Ms Louise Kelly, Cork University Hospital</i>
10:00 to 10:20	Fat grafting after breast cancer surgery <i>Prof Malcolm Kell, Mater Misericordiae University Hospital, Dublin</i>
10:20 to 10:30	Discussion

Tuesday 16th May 2017

Session 14

09:00 to 10:30 Studio

Symposium Mammographicum session: New imaging techniques – what you need to know

Chairs: Dr Barbara Dall & Prof Kieran Horgan

09:00 to 09:15	Tomosynthesis – should it be used in routine screening? <i>Dr Mike Michell, King's College Hospital, London</i>
09:15 to 09:30	Shear Wave Elastography allows fewer biopsies and adds prognostic value <i>Prof Andrew Evans, Ninewells Hospital, Dundee</i>
09:30 to 09:45	Contrast Mammography in the One Stop Clinic <i>Dr Sarah Tennant, Nottingham University Hospitals NHS Trust</i>
09:45 to 10:00	MRI = Mastectomy Rate Increases? <i>Dr Anthony Maxwell, University Hospital of South Manchester</i>
10:00 to 10:30	Discussion

Session 15

09:00 to 10:30: Hall 2B

Mammary Fold session

Chairs: Ms Elizabeth Baker & Mr Baek Kim

09:00 to 09:15	Breast surgery and the 2018 general surgery curriculum <i>Mr Jonathan Lund, Royal Derby Hospital</i>
09:15 to 09:30	Incorporating academic and research activity in a consultant career <i>Mr Stuart McIntosh, Queen's University, Belfast</i>
09:30 to 09:45	Experience from an Australian breast surgery fellowship <i>Miss Isabella Dash</i>
09:45 to 10:00	Preparing for a consultant career as a breast surgeon <i>Mrs Julia Henderson, Royal Liverpool University Hospital</i>
10:00 to 10:15	Mammary Fold Academic and Research Collaborative update <i>Miss Shelley Potter, Royal Liverpool University Hospital & University of Bristol</i>
10:15 to 10:30	Discussion

Session 16

11:00 to 12:30: Auditorium

Oncoplastic & Aesthetic Surgery

Chairs: Mr Lee Martin & Mr David Ward

11:00 to 11:25	Milestones and challenges in oncoplastic surgery: A personal view <i>Mr Dick Rainsbury, Royal Hampshire County Hospital</i>
11:25 to 11:50	Revision/ salvage augmentation surgery <i>Dr Alberto Rancati, Instituto Oncologico Henry Moore, Buenos Aires</i>
11:50 to 12:15	Innovation in oncoplastic surgery: The crucial role of surgical evaluation - everyone's responsibility <i>Prof Chris Holcombe, Royal Liverpool University Hospital</i>
12:15 to 12:30	Discussion

Tuesday 16th May 2017

Session 17

11:00 to 12:30: Studio

Personalised medicine: Biomarkers, biobanking and genomics for the breast surgeon

Chairs: Prof Phil Drew & Mr Stuart McIntosh

11:00 to 11:20	Biomarkers in breast cancer <i>Prof Richard Kennedy, Queen's University Belfast</i>
11:20 to 11:35	Biobanking – What? Where? When? And why is it important for breast surgeons? <i>Dr Jacqueline James, Queen's University Belfast</i>
11:35 to 11:50	Molecular diagnostics for the breast MDT <i>Prof Manuel Salto-Tellez, Queen's University Belfast</i>
11:50 to 12:20	Debate: Genomic Medicine – the future of breast cancer? <i>For: Prof David Gonzales de Castro, Queen's University Belfast</i> <i>Against: Dr Elizabeth Mallon, NHS Greater Glasgow & Clyde</i>
12:20 to 12:30	Discussion

Session 18

11:00 to 12:30: Hall 2B

Nursing hot topics

Chairs: Ms Lis Grimsey & Mrs Joanna Rowley

11:00 to 11:20	Sexuality after breast cancer diagnosis <i>Miss Cathy McDaid, Belfast Health and Social Care Trust</i>
11:20 to 11:40	Management of teenagers with breast disease <i>Mrs Joanna Rowley, Cambridge University Hospital NHS Foundation Trust</i>
11:40 to 12:00	The future of QA visits: What nurses need to know <i>Mrs Margaret Casey, New Cross Hospital, Wolverhampton</i>
12:00 to 12:20	Results of the ABS Nurse Practitioner survey <i>Ms Lis Grimsey, East Sussex Healthcare NHS Trust</i>
12:20 to 12:30	Discussion

Session 19

12:35 to 12:55: Auditorium

**The role of the ABS in promoting research
In memory of Adele Francis**

Chair: Prof Malcolm Reed

Reflections on trial involvement from a patient perspective
Mrs Maggie Wilcox, Independent Cancer Patients' Voice

Presidential address: The role of ABS in breast surgical research - building on the work of Adele Francis
Miss Fiona MacNeill, ABS President

Session 20

13:55 to 14:25: Auditorium

BJS Lecture

Chair: Miss Fiona MacNeill

Are benign breast changes truly benign?
Dr Amy Degnim, Mayo Clinic, Rochester, Minnesota, USA

Tuesday 16th May 2017

Session 21

14:30 to 16:00: Auditorium

Hot topics II

Chairs: Prof John Benson & Ms Jennifer Hu

14:30 to 14:55	HRT and breast cancer: Keeping perspective <i>Miss Jo Marsden, King's College Hospital NHS Trust</i>
14:55 to 15:20	Faslodex (fulvestrant) 500mg: a new standard of care as first-line endocrine therapy for patients with hormone receptor positive Advanced Breast Cancer <i>Prof John Robertson, Royal Derby Hospital</i>
15:20 to 15:40	First results from the iBRA study; a national multicentre prospective cohort study of 2230 patients having immediate implant breast reconstruction <i>Miss Shelley Potter, Royal Liverpool University Hospital & University of Bristol</i>
15:40 to 16:00	Most quoted, most read and most cited papers of the year <i>Dr Sheila Stallard, Gartnavel Hospital, Glasgow</i>

Session 22

14:30 to 16:00: Studio

Submitted papers

Chairs: Mr Ramsey Cutress & Mr Paul Thiruchelvam

14:30 to 14:40	25. Local retrospective 5 year audit of breast cancer recurrence in patients post surgery (wide local excision/mastectomy) for Ductal Carcinoma In Situ (low, intermediate & high grade) <i>Mrs Karen Ives-Smith, Derby Teaching Hospitals NHSFT</i>
14:40 to 14:50	26. Correlation of BCCT core objective scoring software for aesthetic outcome after breast conservation with panel assessment and patient satisfaction <i>Miss Rachel O'Connell, Royal Marsden NHS Foundation Trust, Sutton</i>
14:50 to 15:00	27. Self-directed aftercare: An audit which shows the pilot introduction of patient group recovery health needs assessment clinics being acceptable to our patients and meets the Department of Health, Social Services and Public Safety five standards <i>Mrs Eimer McGeown, Southern Health and Social Care Trust, Portadown</i>
15:00 to 15:10	28. Challenges of setting up a breast unit in a low to middle income country: Lessons learned from Ghana <i>Miss Natasha Jiwa, St Bartholomew's Hospital, London</i>
15:10 to 15:20	29. Role of the Breast Clinical Nurse Specialist in bilateral risk reduction mastectomy decision-making <i>Miss Charlotte Weston, The Royal Marsden NHS Foundation Trust, London</i>
15:20 to 15:30	30. Differences in post mastectomy reconstruction rates between Asian and Caucasian patients: a 5 year institutional review <i>Mr Wisam Ismail, Bradford Teaching Hospitals NHS Trust</i>
15:30 to 15:40	31. Promoting breast awareness with female teenagers and the provision of breast health lifestyle advice <i>Mrs Lucy Montgomery, Southern Health & Social Care Trust, Portadown</i>
15:40 to 15:50	32. Short message service (SMS) messaging to a personal device is an acceptable and preferred mode of communication for invitation to surveillance mammography and 'normal' results <i>Miss Natalia Robson, Royal Bournemouth County Hospital</i>

Pioneering
Non-Invasive
Surgery



HAVE YOU HEARD OF ECHOTHERAPY ?



Non-invasive Surgery For Breast Fibroadenoma Using Therapeutic Ultrasound

**Without Scars
Without General Anesthesia
Without Hospitalization**

**Learn more about
echotherapy on
Booth #27 - ABS 2017**

More information on www.theraclion.com or by sending an email to contact@theraclion.com



C-Trak Galaxy

Gamma Probe System

The C-Trak Galaxy System provides accurate and precise detection of radiation for use in sentinel node biopsy procedures.



Made in the UK



OmniProbe

Visit
STAND 25
for a demo


Key features include:

- Unrivalled directionality at pinpointing nodes.
- Ability to store and retrieve timed counts.
- Ability to detect I-125 in seed localisation procedures.
- Large touchscreen display.
- UK manufactured with local service/support.

OmniProbe PET



OmniProbe EL



Southern Scientific Limited

Scientific House, The Henfield Business Park, Shoreham Road, Henfield, BN5 9SL, UK
E-mail: info@southernscientific.co.uk, Tel: +44 (0)1273 497600, Fax: +44 (0)1273 497626
Web: www.southernscientific.co.uk

A LabLogic Company

Overseas Speakers



Dr Mark Clemens

Mark W Clemens, MD, is an associate professor of plastic surgery at MD Anderson Cancer Center, University of Texas in Houston. He completed plastic surgical training at Georgetown University, research training programs at the National Institutes of Health (NIH) and Harvard Children's Hospital, and received a microvascular reconstructive surgery fellowship at the University of Texas MD Anderson Cancer Center.

Dr Clemens has lectured internationally and written more than 60 peer-reviewed articles and 40 book chapters. He serves on the editorial board and as the breast section editor of the Aesthetic Surgery Journal and is a board member for the Aesthetic Surgery Education Research Foundation (ASERF). He is a committee author for National Comprehensive Cancer Network (NCCN) Guidelines. He was a member of the surgical team that performed the world's first skull and scalp transplantation. Dr Clemens' research interests include robotic, microvascular, and prosthetic reconstructive surgery of the breast. Dr Clemens is the MD Anderson site principal investigator for the NIH Ro1-funded Mastectomy Reconstruction Outcomes Consortium (MROC) Study. He leads a multidisciplinary research team and tissue repository focused on the study of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL). Dr Clemens serves as an American Society of Plastic Surgeons (ASPS) society liaison to the US Food and Drug Administration, and chairs a subcommittee for ASPS overseeing national research and education efforts for BIA-ALCL.



Dr Amy Degnim

Dr Amy Degnim has been a member of the Mayo Clinic staff since 2003. Currently, she serves as consultant in the Department of Surgery and is the Joe M and Ruth Roberts Professor of Surgery, Mayo Clinic College of Medicine. Dr Degnim's clinical practice consists of benign and malignant breast disease. She led development of a nationally recognized breast surgery program at Mayo Clinic with national and international presence. She developed the Multidisciplinary Breast Fellowship at Mayo Clinic and served as Program Director for five years. She has also led recruitment of three other fellowship-trained breast surgeons, and under her leadership the breast surgery program has grown to national renown.

Dr Degnim's main research effort focuses on improving the ability to predict breast cancer risk for individual women by studying premalignant changes in breast tissue. She leads the Mayo Clinic BBD Cohort, a multidisciplinary research study involving approximately 15,000 women, with the goal of improving the accuracy of breast cancer risk prediction and prevention. Aspects of this large research effort include the study of histology, immunology, genomics, and mammographic changes that are associated with risk of developing breast cancer. Dr Degnim also leads clinical research efforts related to prevention, especially vaccines for breast cancer prevention.



Prof Jaume Masia

After achieving the Medical Degree at Barcelona University Prof Jaume Masia did Plastic Surgery training at Sant Pau University Hospital in Barcelona. He completed his training doing fellowships in Canniesburn Hospital (Glasgow) and in Queen Victoria Hospital (East Grinstead).

In 1999 he introduced DIEP flaps for breast reconstruction in Spain. He got a post as consultant in plastic surgery at Sant Pau University Hospital in 2001. Two years later he became the Chief of Microsurgery Unit and in 2007 he won the position as Chief of Plastic Surgery Department and Professor in Plastic Surgery at Universitat Autònoma de Barcelona.

Prof Masia was President of the Spanish Society of Plastic Surgery from 2011-13 and currently he is the President of Spanish Society of Plastic Surgery Foundation for Education. Since 2010 he has been the Director of the International Master Degree on Reconstructive Microsurgery at Universitat Autònoma de Barcelona. He has been invited as lecturer and visiting Professor to more than one hundred international meetings in plastic surgery. Author of several papers and books; his current main interests are perforator flaps, lymphedema surgery and medical education.

Currently his main interest working areas are breast surgery, lymphedema and some genital reconstruction. During many years he has also worked in lower limb reconstructions and H&N oncology reconstruction. Perforator flap reconstruction has been his expertise after 20 years working on it. From 2005 he has been the Chief of Plastic Surgery Department at Sant Pau Hospital and Professor in Plastic Surgery in Universitat Autònoma de Barcelona. As elective post he is the Past-President of the Spanish Society of Plastic Surgery and Director of the European School of Reconstructive Microsurgery.

Overseas Speakers



Dr Alberto Rancati

Alberto Rancati MD PhD graduated in 1984 from medical school at University of Buenos Aires, Argentina. He is Board certified in General Surgery, Mastology, and Plastic Surgery. He undertook his training in Plastic and Oncologic surgery in Argentina, Italy and the USA. He is member of ASPS, (American Society of Plastic Surgeons), ISAPS, (International Society of Aesthetic Plastic Surgery), SACPER (Sociedad Argentina de Cirugia Plastica, and AAC (Asociacion Argentina de Cirugia).

He is currently Chief of Oncoplastic Surgery of the Instituto Oncologico Henry Moore, at Buenos Aires Argentina, and Director of Plastic Surgery for Latin America at the CFS -UCSD (Center for the Future of Surgery at University of California, San Diego, USA.)

His Private practice is based in Buenos Aires, Argentina.

Dr Rancati has published comprehensively within the Plastic Surgery Literature throughout his career and presents his work internationally at Mastology and Plastic Surgery Conferences.

He is actively involved in teaching both at undergraduate and postgraduate level.

His broad training and international fellowships have enabled him to develop special interests within the field of oncoplastic breast and aesthetic breast surgery.



Dr Pat Whitworth

Dr Pat Whitworth is a breast surgical oncologist and Director of the Nashville Breast Center. He has served as Chair of the Board of Directors for the American Society of Breast Surgeons (ASBS, 2005-2008), Vice Chair of the Breast Committee for the American College of Surgeons Oncology Group, and Chair of the Research Committee for the ASBS. Co-author of numerous articles on diagnosis, staging and therapeutic options in breast cancer, his research interests include genetic testing, targeted treatments based on tumor molecular analysis, image-guided, minimally invasive surgical techniques for diagnosis and management, as well as prevention of chronic lymphedema. He has served as Principle Investigator, Investigator or co-investigator for numerous NCI and industry sponsored clinical trials.



Dr Roger Wixtrom

Dr Roger Wixtrom, from LSCI, is a board-certified toxicologist specializing in the safety evaluation (preclinical, clinical, scientific/medical literature) of a range of medical products, including many within the fields of Plastic & Reconstructive Surgery and Ophthalmology. He received his PhD in Pharmacology and Toxicology from the University of California, Davis in 1987 and was a postdoctoral fellow at the University of Texas Southwestern Medical Center at Dallas. Dr Wixtrom has more than 27 years' experience specifically evaluating breast implants and has presented before the FDA, Health Canada and the Institute of Medicine as well as to surgeons in more than 25 countries.

List of Exhibitors

Trade Exhibition

The Exhibition will be held in Hall 1 and will be open at the following times:

Monday 15th May 2017: 07:45 to 19:00

Tuesday 16th May 2017: 08:30 to 14:00

Advantech Surgical Ltd

Advantech Surgical and Belle are pleased to be showcasing the following products:

- MicroAire Power Assisted LipoPlasty system (PAL)
- MicroAire LipoFilter large volume disposable, fat harvesting and processing system that is easy, fast and entirely closed
- Motiva Breast implants. With less than 1% capsular contracture and rupture after 5 years, Motiva are a very safe option
- PureGraft small and large volume fat grafting system
- Motiva's patented micro-cannulae for fat harvesting and reinjection around implants. Produced by Tulip on behalf of Motiva

Stop by our stand to learn more about these and other products.

Allergan Ltd

Allergan is dedicated to developing meaningful treatments to help people reach their potential.

With over 11,100 talented employees in 100 countries, our portfolio includes pharmaceuticals, biologics and medical devices. With 35 years of medical aesthetics experience, Allergan delivers scientific excellence and patient satisfaction through our products, which include:

- JUVÉDERM® and the VYCROSS™ ranges of hyaluronic acid (HA) dermal fillers
- earFold™ an Innovative Medical Device for the Correction of Prominent Ears
- NATRELLE™ collection of breast implants including round and anatomical

Our products are further supported by the Allergan Medical Institute which is dedicated to providing a progressive learning forum for healthcare specialists in the field of aesthetic and reconstructive medicine.

AstraZeneca Pharmaceuticals

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that have the potential to transform patients' lives and the Company's future. With at least 6 new medicines to be launched between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to advancing New Oncology as one of AstraZeneca's six Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms – immune-oncology, the genetic drivers of cancer and resistance, DNA damage response and antibody drug conjugates – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

Breast Cancer Now

We're Breast Cancer Now, the UK's largest breast cancer charity – and we're dedicated to funding research into this devastating disease. We believe that if we all act now, by 2050, everyone who develops breast cancer will live. But we'll only reach that point by working in a new, collaborative way. We're bringing together all those affected by the disease to improve the way we prevent, detect, treat and stop the disease. So we can move from a time when people fear breast cancer to a generation where everybody lives.

BreastHealth UK

BreastHealth UK is a diagnostic company with a difference.

BreastHealth UK offers risk-stratified breast cancer screening for the private and corporate market, and operates a network of private diagnostic OneStop breast clinics for Cigna UK members, as well as a larger UK PMI company.

Check4Cancer also offers genetic testing with counselling via a network of genetic counsellors through its sister company, GeneHealth UK. Patients are counselled to select testing either for BRCA1& 2 or BreastGene, a panel of 10 clinically relevant breast cancer genes.

BreastHealth UK will be launching a new personal breast cancer risk assessment test in 2017.

Care Wise

Southern Scientific Ltd acquired Care Wise in 2015. Previously the European distributor of the company's gamma probe systems, Southern Scientific has many years of experience and expertise working with the product range. Also part of the LabLogic group, the company is a key supplier to the healthcare sector worldwide.

Our products include:

C-Trak Galaxy Gamma Probe System which provides accurate and precise detection of radiation for use during sentinel node biopsies in breast, melanoma and other types of cancer.

C-Trak Auto Analyser which is designed to maximize background radiation correction and give high sensitivity for locating the lymph nodes.

List of Exhibitors

ClearCut Medical

ClearCut Medical's platform technology is based on innovative Magnetic Resonance (MR) imaging protocols that enable accurate and rapid surface imaging for real-time assessment of tissue microstructure in the operating theatre or pathology lab.

The ClearSight™ MRI System is focused on breast cancer lumpectomy for intraoperative margin assessment of surgically removed lumps. By providing accurate, real-time margin analysis to the surgeon in the OR, the system is expected to significantly improve surgical outcomes and reduce re-excision rates.

DAAX Ltd

UK/Ireland representatives for FAXITRON - leading manufacturers of innovative solutions for digital specimen radiography.

BioVision, for surgical radiography enabling a surgeon to accurately determine margin assessment within 10 seconds minimising the risk of re-excision and saving at least 20 minutes per procedure

CoreVision for breast care units to identify calcification within needle biopsy

PathVision for histopathology where the large field of view provides imaging capability from small wax block assessment to full mastectomy and fetal specimen imaging

"VISION" systems - simple to operate providing clinicians with a unique level of image quality

For information visit: www.daax.co.uk

Eurosurgical Ltd

Eurosurgical Ltd are a UK based supply company for new and established surgical devices, specializing in breast, reconstruction and plastic surgery. TIGR Mesh is a 100% synthetic long-term resorbable matrix made from two well-known suture materials that are strong over 9 months and fully disappears over 2 years. TIGR is an excellent mesh for both sub-muscular support and pre-pectoral cover, available in a range of sizes that are cost effective and with low reported complications. We also offer a wide range of single-use Fat Grafting equipment and cannula for small to large fat harvesting, including Lipivage and Aquavage.

FaHRAS Ltd

FaHRAS supplies a sophisticated evidence-based software system which enables a user to run a variety of analyses against their family history to quantify their risk of developing breast cancer.

GC Aesthetics™

Our company is the UK's leading manufacturer of breast implants. We supply thousands of implants every year,

changing lives around the globe. We have over 60 years combined market presence with Nagôr and Eurosilicone products. Overall we have 24% for the world market excluding the US, up from 18% just 3 years ago. We work in partnership with the medical community to continually develop high quality products and services that meet both surgeons' and women's needs. As a global leader in the female aesthetics industry, GC Aesthetics not only provides over 1100 products across our brands Eurosilicone® and Nagôr®; but also delivers services to help women make informed choices.

Genomic Health

Genomic Health UK Ltd, located in London, is part of the global company Genomic Health. The company is committed to improving the quality of cancer treatment decisions through the research, development and commercialisation of genomic-based clinical laboratory services.

Through its Oncotype IQ™ platform, Genomic Health aims to deliver actionable genomic intelligence that informs cancer treatment decisions across the patient journey. Currently, the Oncotype IQ portfolio consists principally of Oncotype DX® - the company's flagship line of gene expression tests.

Updated NICE Breast Quality Standard [QS12] recommends Oncotype DX® testing (June 2016, www.nice.org.uk/Guidance/QS12)

www.genomichealth.co.uk

Healthcare 21

Healthcare 21 is delighted to be a corporate sponsor of ABS this year in Belfast. With us today we have LifeCell's market leading ADM, STRATTICE™ Pliable (the most clinically studied ADM) and their new ADM, ARTIA™ which has been deliberately designed to optimise breast reconstructive outcomes.

We also have LifeCell's REVOLVE™, engineered to yield rapid, reliable results in high volume fat processing. Also on display today is Acelity's PREVENA™, an incisional management device for your high risk patients that removes fluids and infectious materials from the incision. We look forward to welcoming you to our stand.

Ideal Medical Solutions Ltd

Ideal Medical Solutions are a UK distributor, with an extensive range of breast surgery products.

Please visit our stand to find out further information on the following clinically proven products and to collect your free samples: Filtron® Fat Transfer and full range of single use cannulas; Keller Funnel 2® no touch implant delivery sleeve, the Onetrac® single use retractor with built in light source and Galaflex® mesh.

continued...

List of Exhibitors

IGEA Medical

Through extensive research IGEA have developed CLINIPORATOR™ to deliver Electrochemotherapy. It has been well documented that cutaneous metastases have the greatest impact on a patient's day to day quality of life. CLINIPORATOR™ offers patients with cutaneous and subcutaneous metastases an option to improve quality of life when perhaps other treatments have been exhausted.

Independent Cancer Patients' Voice

Independent Cancer Patient Voice is a patient led charity for people who have been affected by cancer and want to add an informed and realistic patient perspective to cancer research. We do this by providing education, mentoring and support to enable a more effective participation and give members confidence in discussion with researchers so that we can ensure patient benefit and aid recruitment.

We have earned the respect of our professional colleagues who now request our involvement from the early stages of their cancer research and are happy to host us for study days at academic units around the UK. ICPV has a member only google group where we can circulate research papers for comments which are collated and returned to the researcher.

We are particularly interested in involvement with Trainees and "Next Generation Consultants" in order to build an effective partnership early in their careers. As patients, we are very aware of the important role of surgery in our treatment pathway and of the increasing interest in research in surgical oncology and we would be pleased to assist in this research.

www.independentcancerpatientsvoice.org.uk

Lightpoint Medical

Lightpoint Medical is an innovative medical device company dedicated to improving health outcomes for cancer patients through image-guided surgery. The company's ground-breaking molecular imaging technology has the potential to detect cancer in real-time during surgery and thereby reduce the need for repeat operations.

Today, surgeons primarily rely on visual and tactile assessment to find cancerous deposits. The Lightpath™ Imaging System is designed to fill this important medical need. By providing a means to assess tumour status intra-operatively, via molecular imaging, it aims to enable surgeons to know with confidence that they have removed all cancerous tissue.

Mammary Fold

The Mammary Fold is the UK Breast Surgery trainees' association run by the trainees. It aims to support our members who have a dedicated interest in breast surgery and works in close conjunction with the Association of Breast Surgery. We have regional representatives to support breast surgery trainees across the UK. Furthermore, the Mammary Fold Academic Committee provides

opportunities for trainees to engage in research with an expanding portfolio of national collaborative trainee-led breast research studies. We welcome all trainees interested in Breast Surgery to speak to us at the stand and join the Mammary Fold by contacting themammaryfold@gmail.com

Mana-Tech

Mana-Tech will be demonstrating a number of innovative products:

The Node Seeker, with simultaneous Iodine 125 seed localization and Tc-99m sentinel node mapping, makes lymphatic mapping a simple and accurate procedure. The highest published sensitivity of probe makes the smallest lymph node easily detectable and superior shielding and collimation makes detection of lymph nodes possible even in proximity of the site of injection. We can also supply Iodine 125 seeds pre-loaded.

The HyperEye Near Infra-Red Colour camera for easy Sentinel Lymph Node localisation and blood flow verification without radioactive isotopes.

The IceSense3™ system - "Delivering the Promise of Rapid, Office Cryoablation for breast tumors".

We will also exhibit a range of biopsy and site-marking products.

Medasun Ltd

Medasun Ltd – winner of 2017 contract to supply Marena Post-surgical bras to the NHS supply chain.

Medasun Ltd is the UK and Irish exclusive distributor for post-surgical Marena Comfortweave® medical compression garments and bras. Marena Bras are specifically designed for surgical procedures with patented power stretch material which is breathable, anti-microbial, soft and comfortable for your patient.

Easy to fit bra styles include BNVL, specifically designed for mastectomy patients, the BNRZ bra, which has prosthetic pockets and the most popular B2 bra.

We look forward to meeting you and showing the full range of Marena bras available to the ABS members in Belfast.

Mentor

As a leading manufacturer of breast implants, Mentor is delighted to be associated with the ABS Conference. We look forward to the debates, solutions and expertise shared from around the globe, and would encourage all delegates to visit the Mentor stand and understand our growing portfolio of breast care solutions.

MHRA

The Medicines and Healthcare Products Regulatory Agency (MHRA) is an arms-length government agency, which regulates all medical devices and medicines in

List of Exhibitors

the UK. MHRA works in collaboration with European and other regulatory agencies across the world including the FDA (US), TPD (Canada) and TGA (Australia), to ensure that medical products are brought safely to the market, investigate adverse events and take appropriate corrective actions in the interest of patient safety.

Myriad Genetics Ltd

About Myriad International: Myriad Genetics, a leading molecular diagnostic company founded in 1991, is dedicated to saving and improving lives by discovering and delivering valued, transformative tests across all major diseases.

Myriad's testing portfolio is uniquely qualified to address the following key areas in oncology – cancer prevention, early diagnosis, the development of new treatments and optimisation of current treatments by personalising and increasing effectiveness.

Myriad International operates a state of the art laboratory in Munich, Germany.

Contact Myriad UK and Ireland:
info@myriadgenetics.co.uk • www.myriadgenetics.co.uk

National Audit of Breast Cancer in Older Patients (NABCOP)

The National Audit of Breast Cancer in Older Patients (NABCOP) will evaluate the process of care and outcomes for women with breast cancer, aged 70 years or over, in England and Wales. It will investigate the management for older patients with breast cancer and highlight potential areas for improvement.

Its first Annual Report describes the results from an organisational audit of NHS hospitals as well as how clinicians responded to a series of case vignettes. Each vignette explored what treatment options would be recommended to an older women with a specific type of breast cancer and pattern of comorbidities.

For further information, please visit: www.nabcop.org.uk

Oncology Systems Limited (OSL)

Oncology Systems Limited specialise in supplying radiotherapy technology for the treatment of cancer and is the exclusive distributor of the Carl Zeiss INTRABEAM system throughout the UK and Ireland. Although primarily used for the treatment of breast cancer at the time of breast conserving surgery (TARGIT), potentially negating the need for several weeks of external beam radiotherapy treatment, the INTRABEAM system also has applications in the following areas; head and neck, colorectal, kypho, GYN and superficial. Stop by the OSL booth to find out more.

For further information e-mail: enquiry@osl.uk.com
www.osl.uk.com

Oncotherapy Resources Ltd

Oncotherapy Resources Ltd (ORL) are the providers of managed services for single dose intraoperative radiotherapy (SD-IORT) at the time of surgery and the UK distributor of the Xofigo Axxent electronic brachytherapy IORT system and accessories.

Operating Room Systems Ltd

Operating Room Systems Ltd., specialise in the supply of surgical equipment and associated consumables to hospitals and private clinics across UK and Ireland. Our product portfolio spans across the clinical spectrum with particular specialism within the area of Minimally Invasive Surgery.

Within Breast Surgery we offer a range of solutions for effective retraction combined with delivery of light to the operative field. As sole distributor for World of Medicine, we represent Gamma Finder® in this market. The Gamma Finder® probe is best suited for Sentinel Node and Parathyroid Localization in Surgical Oncology. Its unique design puts simplicity and accuracy at the surgeon's fingertips. The Gamma Finder® probe will detect and give a numerical indication and an acoustic signal when in proximity of a gamma ray emitting source. Compact, lightweight and versatile, the Gamma Finder® probe is easily transported from operating room to operating room in its own sturdy carry case.

Our philosophy at Operating Room Systems is clear. We are committed to building long term sustaining relationships with our customers, bringing them innovation, value and quality; along with delivering effective technical support and robust after sales service provision.

pfm medical UK Ltd

pfm medical UK Ltd is the UK subsidiary of pfm medical ag. We are specialist manufacturers and distributors of vascular access, wound drain, histology and surgical implant (titanized mesh) products. Located in the Cheshire countryside, we are committed to supplying high quality products to the NHS, Private Hospitals, Research and Development Centres, Laboratories, Veterinary Surgeries, Pharmaceutical and all other care services.

We have been established since 2007 and have a strong team of clinical sales consultants and expert support staff. For more information visit – www.pfmmedical.co.uk

Physiquipe Ltd

Physiquipe brings together the best technological equipment for physical assessment and rehabilitation from around the world. We offer this through our equipment solutions, rehabilitation clinics and training academy. We bring innovative products to address some of the UK's biggest medical challenges, including; cancer and lymphoedema, body composition and sports science research. We work with CCGs, National Health Service, Private Hospitals, Universities and Elite Sports Clubs – all

continued...

List of Exhibitors

with the core objective to raise the standard of healthcare whilst reducing costs. Our goal is to deliver the best clinical solutions to enhance objectivity and outcomes which have a real impact for both clinician and patient.

Q Medical Technologies Ltd

Q Medical Technologies Ltd is an independent UK company founded in 2004. Q Medical distributes and markets SurgiMend PRS – for Plastic & Reconstructive Surgery & Polytech Breast Implants that come with the most extensive warranty cover to protect you and your patient. Developed to meet the specific needs of plastic surgeons.

Q-Surgical Ltd

Q-Surgical brings innovative products to the marketplace enabling a high level of clinical care to be received by the patient. MarginMarker, CorrectClips and Quill barbed sutures are some of the products, which will be available to view on our stand.

Raise Healthcare

Raise Healthcare is an exclusive distributor for a range of Biologic (Acellular Dermal Matrix) meshes for UK market. Manufactured in Germany, our products for Breast Reconstruction include NATIVE and BRAXON.

NATIVE is Porcine derived, freeze dried ADM for Sub-Pectoral Breast Reconstruction available in various sizes.

BRAXON is the patented world's first ADM for Pre Pectoral Breast Reconstruction for complete coverage of the breast implant without detaching the Pectoralis Muscle.

For more information please visit us in exhibition hall.

Email: enquiries@raisehealthcare.co.uk
Telephone: 0121 629 7818
www.raisehealthcare.co.uk

Roche

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life, safety and survival of patients. Twenty-nine medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. Roche in the UK employs over 2,000 people in pharmaceuticals and diagnostics. For more information: www.roche.co.uk

Sebbin UK Ltd

Sebbin is a Paris-based medical device company focused on reconstructive and aesthetic surgery. Sebbin has supplied

high quality devices for over 30 years and is present in nearly 60 countries worldwide.

Our comprehensive product portfolio includes silicone breast implants, a unique biological scaffold and a full range of disposable lipofilling devices.

We are one of only 3 companies to offer 10-year clinical data on our breast implants. Our new 10-year study is currently the largest prospective breast implant study in the world.

Visit our stand and our experienced team will introduce you to our portfolio.

Smith & Nephew

Smith & Nephew is a diversified advanced medical technology business that supports healthcare professionals in more than 100 countries to improve the quality of life for their patients. We do this by taking a pioneering approach to the design of our products and services, by striving to secure wide access to our diverse technologies for more customers globally, and by enabling better outcomes for patients and healthcare systems. Smith & Nephew provide a range of products for preventing, treating and managing wounds.

Please visit us at stand 29

www.smith-nephew.com
E-mail: advice@smith-nephew.com

Symposium Mammographicum

Symposium Mammographicum is a registered charity founded in 1979. Its principal aims are 'to stimulate and support research, and disseminate knowledge about the prevention, diagnosis and treatment of breast disease'.

We organise biennial conferences around the UK and are pleased to announce that the 19th Symposium will be held at the ACC Liverpool from 8-10 July 2018. Symposium Mammographicum 2018 is the conference and exhibition at the forefront of breast imaging technology. The programme will reflect the multi-disciplinary nature of breast diagnostics, and will be complemented by a technical exhibition and workshops.

SM also runs Award and Bursary schemes to enable clinicians to carry out research, attend the conference or undertake an educational clinical placement.

<http://www.sympmamm.org.uk>
email: Sympmamm@profileproductions.co.uk
tel: 020 3725 5840

Sysmex UK Ltd

Sysmex continues to strive to improve cancer treatment with advanced technologies.

Accurate, standardised, whole node staging of patients (Post-Operative or Intra-Operative). Appropriate axillary clearance. Prognostic stratification of patients (5 year DFS).

List of Exhibitors

"The only independent predictor of 4 or more involved nodes". "A better predictor than the number of positive LN" AND in an intra-operative setting, 75-80% of breast cancer patients undergoing surgery can be informed in the recovery room that their nodal status is clear!

OSNA remains the only system approved by NICE for SLN analysis with more than 130,000 patients already benefitting from this approach.

The Sentimag System is proven for accurate localisation of SLN during surgery and has the capability to replace the dual technique as there is no requirement for radioisotope or blue dye.

Visit us at Stand 7 to find out more!

www.sysmex-lifescience.com

Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules.

THEYA Healthcare

With input from 80 breast cancer patients, as well as healthcare professionals, THEYA Healthcare developed a revolutionary new range of post surgery underwear. In clinical trials, this flagship range has proven to aid healing and support recovery. The seam, tag and wire free design, combined with the softness of the bamboo mix fabric, means the bras will not irritate wounds or sensitive skin. The longer, elastic free band means it won't roll up or interfere with drains, lessening the incidence of haematoma or seroma. The 70% bamboo mix fabric is anti-bacterial and keeps the wearer drier and cooler than 100% cotton making the bras ideal for use by patients undergoing radiotherapy. These along with the many other design features result in a bra that responds perfectly to the needs of women undergoing treatment for breast cancer.

Thuasne UK Ltd

SILIMA is Thuasne's flagship brand within Breastcare, comprising natural-feel breast forms and well fitting lingerie, and offers a comprehensive range of post-mastectomy products.

Trulife

Trulife is an internationally based group with over 50 years' experience in the creation, development, manufacture and marketing of niche healthcare and consumer products. The Group's activities encompass Orthopaedics, Prosthetics, Breastcare & Pressurecare.

In 1958 Trulife developed the world's first commercially successful external breast prosthesis. The Breastcare range at Trulife is still the heart and soul of the company today.

We are constantly investing in innovation as we want our products to help restore confidence, self-esteem and offer a better quality of life for women following breast surgery.

Trulife offer a wide range of breast forms, and partial breast forms, suitable for use after mastectomy, lumpectomy and reconstructive surgery.

For more information please visit our website: www.trulifebreastcare.com

WomanZone

Womanzone are UK distributors for ABC Breast Care. Dedicated to helping women lead fuller lives after breast surgery.

Listening to our customer's needs, developing the Post Op Kit and the most innovative, high quality products, creating the most natural super soft and beautiful breast forms available. Our passionate team of dependable professionals have specialist product knowledge and can assist with any product needs, fitting requests and training.

With over 50 years' experience, providing an unrivalled service of care including a mail order brochure, offering advice, free fitting, made to measure swimwear, lingerie and pocketing services. Please contact us for further information.

The ABS would like to thank all exhibiting companies for their support of this meeting

General Information

Registration Desk

Registration will be open in the Riverside Foyer at the following times:

Monday 15th May 2017: 07:45 to 19:00
Tuesday 16th May 2017: 08:00 to 16:15

In the interests of security, delegates should wear their name badges at all times whilst in the conference centre.

Lunch and Refreshments

Lunch and refreshments will be served in Hall 1 at the times listed in the programme. Additional tea and coffee points can be found in Hall 2A.

A/V Preview Room

An A/V Preview Room is available in Boardroom 2 for the duration of the meeting. Speakers are requested to hand their presentations into the room on arrival.

ABS Conference App

The ABS Conference App can be downloaded from your app store. It includes programme information, a 'my schedule' facility, speaker information, delegate list and exhibitors list. You can view the abstracts and electronic posters via the Conference App and also give your conference feedback.

Posters

The electronic posters will be on display in Hall 1, the 1st floor lobby and Hall 2A. Delegates requiring assistance viewing the posters should speak to the Multi-poster representative in Hall 1. The electronic posters can also be viewed via the Conference App.

Cloakroom

A cloakroom and luggage store will be available in the Riverside Foyer for the duration of the meeting.

Wi-Fi

Delegates wishing to use the Wi-fi should log onto the Waterfront network and then click on the public user tab. Delegates will need to enter their e-mail address and accept the terms and conditions in order to gain access.

Prayer Room

A prayer room is available for the use of delegates in Boardroom 3 on the 2nd floor.

Photography

A photographer will be taking images of the conference during the event for use by the ABS at this meeting, in publications and on its website. If you do not wish to have images of yourself used by the ABS please let Lucy Davies know by e-mail at: lucydavies@absghi.org.uk

Asking questions in the Auditorium

Delegates wishing to ask a question in the main auditorium can do so via the internet. Please go to: <https://www.sli.do> or type **Slido** into a search engine. Then enter the event code **#6059** and you will be able to ask a question of the panel.

Alternatively use: <https://app.sli.do/event/st6cluzp> which will take you directly to our event page.



CPD

The Association of Surgeons of Great Britain and Ireland have awarded 6.5 CPD Points for Monday 15th May 2017 and 5.5 CPD Points for Tuesday 16th May 2017.

A CPD certificate has been issued to all delegates with their name badge. Please ensure that you retain this as duplicates cannot be provided.



You can follow the ABS on Twitter @ABSGBI. Please tweet during the ABS Conference using the hashtag #ABSConf17 to be included in the Twitter Feed.

ABS Annual Dinner Monday 15th May 2017, Titanic Belfast 7.30pm for 8pm

The ABS Annual Dinner will be held at Titanic Belfast on Monday 15th May 2017 at 7.30pm for 8pm. Titanic Belfast is at 1 Olympic Way, Queens Road, Titanic Quarter, Belfast, BT3 9EP. Attendees must have bought a ticket in advance of the event. The dress code is lounge suits.

Complimentary coaches are available from 6pm to take guests over to Titanic Belfast. The last pick up will be at 7.45pm. The coaches will run a shuttle service from the following locations:

- Europa Hotel (Glengall Street)
- Hilton Belfast Hotel (Lanyon Place, adjacent to the Belfast Waterfront)

The Gallery Tours at Titanic Belfast are available from 6.15pm. Last entry to the galleries will be at 7.30pm. Delegates must have pre-booked a ticket to gain access to the galleries.

Guests requiring a taxi at the end of the dinner should go to the car park in the basement of Titanic Belfast where a Value Cab host will be able to order taxis as required.



INCLUDED in international guidelines (ASCO, ESMO, St. Gallen, AGO).

VALIDATED in four large clinical studies with more than 3,100 patients.

USED to guide treatment selection in more than 13,000 patients worldwide.

What is the best treatment option for a woman with ER+, HER2- breast cancer?

EndoPredict®

identifies the largest group of women with breast cancer at low risk* of distant recurrence who might safely avoid chemotherapy

- Two clear risk categories: low and high risk
- Combines tumour gene expression analysis and clinico-pathological prognostic factors
- Excellent performance in node negative and node positive patients
- Accurate risk assessment for early and late distant recurrence
- Performed in local molecular pathology laboratory or at a reference laboratory

*Low risk: <10% chance of distant recurrence in 10 years

Filipits et al., Clin Cancer Res 2011; Denkert et al., Virchows Arch 2012; Dubsky et al., BJC 2013; Dubsky et al., Ann Onc 2013; Baus et al., JNCI 2016; Sestak et al., SABCS 2016



www.endopredict.com
www.myriadgenetics.eu
info@myriadgenetics.co.uk

Diary Date



**ABS Conference
18th & 19th June 2018 • ICC Birmingham**



Choose with confidence

SAFETY

PATIENT
SATISFACTION

Choose Motiva Implants® - you never have to decide between safety and patient satisfaction

0% Late seromas* 0% Double capsules* <1% Capsular contracture and rupture*

*Through 5 years of a 10-year prospective study. Motiva Implants® Silicone Breast Implant Summary of Clinical Data: 5-year follow up. Establishment Labs S.A. March 2016.

**This meeting is supported by the
Association of Breast Surgery's sponsors:**



This event has been sponsored by Roche Products Ltd and AstraZeneca Pharmaceuticals who have contributed to stand costs but who have had no involvement in any other arrangements for this meeting



Association of Breast Surgery
at The Royal College of Surgeons
35 – 43 Lincoln's Inn Fields
London WC2A 3PE

T 020 7869 6853
F 020 7869 6851
E office@absgbi.org.uk
W www.associationofbreastsurgery.org.uk